Krensavage Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $36.2M | Buy |
2,866,138
+99,748
| +4% | +$1.34M | 14.16% | 2 |
|
|
2025
Q4 | $43.6M | Buy |
2,766,390
+651,946
| +31% | +$8.28M | 15.41% | 2 |
|
|
2025
Q3 | $25.3M | Hold |
2,114,444
| – | – | 10.78% | 2 |
|
|
2025
Q2 | $16M | Sell |
2,114,444
-2,142
| -0.1% | -$12.9K | 8.46% | 5 |
|
|
2025
Q1 | $11.7M | Sell |
2,116,586
-804
| -0% | -$4.97K | 6.46% | 6 |
|
|
2024
Q4 | $12.2M | Buy |
2,117,390
+619,316
| +41% | +$5.94M | 7.2% | 6 |
|
|
2024
Q3 | $15.5M | Buy |
1,498,074
+246,736
| +20% | +$3.23M | 8.7% | 5 |
|
|
2024
Q2 | $16.2M | Buy |
1,251,338
+126,752
| +11% | +$1.71M | 7.45% | 6 |
|
|
2024
Q1 | $19.6M | Buy |
1,124,586
+381,762
| +51% | +$5.05M | 8.71% | 6 |
|
|
2023
Q4 | $6.99M | Buy |
742,824
+7,721
| +1% | +$71.9K | 2.48% | 10 |
|
|
2023
Q3 | $8.21M | Buy |
735,103
+47,490
| +7% | +$765K | 3.02% | 9 |
|
|
2023
Q2 | $14.7M | Buy |
687,613
+84,312
| +14% | +$2.49M | 4.66% | 9 |
|
|
2023
Q1 | $24.4M | Buy |
603,301
+8,483
| +1% | +$405K | 7.41% | 8 |
|
|
2022
Q4 | $27.7M | Buy |
594,818
+5,458
| +0.9% | +$249K | 8.55% | 6 |
|
|
2022
Q3 | $30.6M | Sell |
589,360
-35,408
| -6% | -$2.07M | 9.73% | 5 |
|
|
2022
Q2 | $29.5M | Buy |
624,768
+75,940
| +14% | +$4.12M | 9.76% | 5 |
|
|
2022
Q1 | $39.1M | Sell |
548,828
-15,274
| -3% | -$994K | 13.46% | 2 |
|
|
2021
Q4 | $42.2M | Sell |
564,102
-372,675
| -40% | -$29.2M | 14.63% | 3 |
|
|
2021
Q3 | $53.2M | Sell |
936,777
-2,873
| -0.3% | -$142K | 16.69% | 1 |
|
|
2021
Q2 | $41.4M | Buy |
939,650
+76,802
| +9% | +$3.76M | 14.04% | 3 |
|
|
2021
Q1 | $42.6M | Buy |
862,848
+4,037
| +0.5% | +$201K | 14.73% | 1 |
|
|
2020
Q4 | $36.2M | Buy |
858,811
+33,482
| +4% | +$1.47M | 10.56% | 5 |
|
|
2020
Q3 | $37.8M | Buy |
825,329
+62,226
| +8% | +$3.02M | 12.03% | 5 |
|
|
2020
Q2 | $38.3M | Buy |
763,103
+62,785
| +9% | +$3.25M | 10.42% | 5 |
|
|
2020
Q1 | $36M | Buy |
700,318
+210,933
| +43% | +$11.2M | 11.58% | 4 |
|
|
2019
Q4 | $30.2M | Sell |
489,385
-9,489
| -2% | -$588K | 10.32% | 6 |
|
|
2019
Q3 | $30M | Buy |
498,874
+19,298
| +4% | +$1.43M | 11.51% | 5 |
|
|
2019
Q2 | $40.5M | Buy |
479,576
+3,534
| +0.7% | +$318K | 13.13% | 4 |
|
|
2019
Q1 | $45.5M | Sell |
476,042
-58,783
| -11% | -$5.27M | 12.29% | 3 |
|
|
2018
Q4 | $37.9M | Buy |
534,825
+23,639
| +5% | +$1.81M | 12.79% | 3 |
|
|
2018
Q3 | $43.7M | Sell |
511,186
-7,849
| -2% | -$786K | 11.23% | 4 |
|
|
2018
Q2 | $60.2M | Sell |
519,035
-220,703
| -30% | -$22M | 15.36% | 2 |
|
|
2018
Q1 | $59.9M | Sell |
739,738
-127,032
| -15% | -$9.78M | 14.52% | 2 |
|
|
2017
Q4 | $50.9M | Sell |
866,770
-147,077
| -15% | -$7.36M | 15.85% | 1 |
|
|
2017
Q3 | $47.4M | Sell |
1,013,847
-91,145
| -8% | -$3.66M | 14.79% | 1 |
|
|
2017
Q2 | $39.8M | Buy |
1,104,992
+6,468
| +0.6% | +$207K | 12.07% | 2 |
|
|
2017
Q1 | $33.8M | Buy |
1,098,524
+42,805
| +4% | +$1.33M | 10.91% | 3 |
|
|
2016
Q4 | $35.4M | Buy |
1,055,719
+55,978
| +6% | +$1.6M | 12.68% | 2 |
|
|
2016
Q3 | $26.6M | Buy |
999,741
+92,811
| +10% | +$2.16M | 9.61% | 3 |
|
|
2016
Q2 | $20M | Buy |
906,930
+24,401
| +3% | +$639K | 7.21% | 4 |
|
|
2016
Q1 | $25.9M | Buy |
882,529
+4,083
| +0.5% | +$114K | 9.3% | 3 |
|
|
2015
Q4 | $29M | Buy |
878,446
+148,138
| +20% | +$4.83M | 9.25% | 2 |
|
|
2015
Q3 | $26.4M | Buy |
730,308
+23,400
| +3% | +$1M | 9.55% | 1 |
|
|
2015
Q2 | $31.8M | Buy |
706,908
+282,892
| +67% | +$11M | 11.99% | 1 |
|
|
2015
Q1 | $13M | Buy |
+424,016
| New | +$16.5M | 5.91% | 7 |
|
Other funds holding ENTA
FCM
DTC
VCM
VPM
SSC
Krensavage Asset Management's ENTA Position: Q1 2026 in Review
Krensavage Asset Management increased its Enanta Pharmaceuticals (ENTA) stake by 3.6% in Q1 2026, buying an estimated $1.34M and bringing the position to 2,866,138 shares worth $36.2M. The position accounts for 14.16% of the portfolio, ranked #2.
Krensavage Asset Management first reported a position in ENTA in Q1 2015 and has held it in 45 quarters since. The position peaked at $60.2M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Krensavage Asset Management held 2,866,138 shares of Enanta Pharmaceuticals worth $36.2M as of Q1 2026.
- Krensavage Asset Management bought 99,748 Enanta Pharmaceuticals shares in Q1 2026, an estimated $1.34M.
- Enanta Pharmaceuticals made up 14.16% of Krensavage Asset Management's portfolio in Q1 2026, its #2 holding.
- Krensavage Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
- Krensavage Asset Management's Enanta Pharmaceuticals position peaked at $60.2M in Q2 2018.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Krensavage Asset Management's 13F filing for Q1 2026, filed 15 May 2026.